Haselmeier AG Self-Injection Devices for the Medical Device Industry

Haselmeier

Haselmeier develops and manufactures self-injection devices, proprietary designs, technology and intellectual property for the medical device industry.

Self-injection systems for the medical device industry

Haselmeier has more than four decades of experience with medical devices and comply with regulatory requirements to create, design and industrialise self-injection systems.

The company’s self-injection systems are used by pharmaceutical and biotechnology companies worldwide.

Haselmeier creates products that enable a convenient and comfortable self-injection experience by integrating patient feedback into the design of devices.

Early concepts are prototyped for testing and human factors studies capture the handling needs and skills of potential users. The company’s range of drug devices provides successful administration of the drug and a positive user experience.

Human factor studies

Haselmeier offers early-stage activities, including think-tank discussions, paper and product concepts and industrial designs, user handling review and risk-analysis, as well as prototyping of initial concepts up to functional devices.

The company also provides user focus groups and human factor studies for concept and prototype evaluation.

Successful development and industrialisation of drug delivery devices is dependent upon the execution of technical, regulatory and operational requirements.

Haselmeier specialises in qualified design control processes and certified systems using a network of partners and manufacturing operations for an efficient market introduction for drug delivery devices.

Commercial development and industrialisation services include regulatory expertise to support approval strategies and controlled design-to-manufacturing transfer, verification and validation.

Drug delivery devices for manufacturing

Haselmeier adheres to high standards for drug delivery devices to ensure reliable and reproducible manufacturing. Potential improvements are identified at all stages of the product’s lifecycle to provide a safe and state-of-the-art drug delivery device.

Haselmeier provides flexible and reliable manufacturing and lifecycle management using:

  • Certified and modern production facilities and manufacturing processes
  • Qualified personnel
  • A strong network of sub-suppliers and manufacturing partners
  • Continuous engineering and product improvement programme
  • Innovation meetings to identify next product generation

About Haselmeier

The Haselmeier Group is headquartered in Switzerland and employs 200 team members worldwide. The company has a presence in Europe, the US, India and China.

Products are produced at state-of-the-art manufacturing sites located in Buchen im Odenwald in Germany, Dnesice in Czech Republic and Bangalore, India.

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

Haselmeier Announces Release of a New Version of Axis-D Pen Injector, GONAL-f® 2.0

Haselmeier released GONAL-f® 2.0 after being approved by the European Medicines Agency (EMA).

Product and Services
Address
Haselmeier AG

Dufourstrasse 32

8008 Zürich

Switzerland

+41 44 250 52 40 +41 44 250 52 49 www.haselmeier.com

Haselmeier AG Images

Video

White Papers

Press Release

22 August 2017

The Haselmeier D-Flex is a disposable pen for use with 3ml cartridges.

Read more
16 August 2017

The new Pergoveris® Pen by Haselmeier has received a positive assessment by Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA).

Read more
13 March 2017

Haselmeier has announced Paul Jansen has been appointed as its senior advisor and member of the board of directors

Read more
3 March 2017

Haselmeier's new D-Flex Just One has won the GOOD DESIGN™ Award.

Read more
7 September 2016

Haselmeier has won German Brand Award 2016 following the GOOD DESIGN™ Award and the Red Dot Award: Product Design in 2015.

Read more
7 June 2016

Based on Haselmeier's i-pen platform, launch of the 300 unit insulin pen BerliPen® areo 3 to the German market has been announced by Berlin-Chemie.

Read more
24 May 2016

Haselmeier released GONAL-f® 2.0 after being approved by the European Medicines Agency (EMA).

Read more
2 July 2015

The Haselmeier Group has decided to reinforce and reorganise its Executive Board.

Read more
23 June 2015

The world's largest and fastest provider of information is the Internet.

Read more
17 June 2015

Haselmeier has announced the opening of its new office in the Boott Cotton Mills at 126 John Street, Suite 11, Lowell, Massachusetts 01852.

Read more
17 June 2015

Haselmeier is proud to announce another award for one of its products.

Read more
11 May 2015

Haselmeier Group has won prizes for two of their products at the Good Design Awards.

Read more
10 November 2014

Haselmeier has been able to successfully grow over the past few years, allowing the company to carve out a solid position in the market for medical devices.

Read more
7 November 2014

Haselmeier has announced that Biocon, one of Asia's premier biotechnology companies, has just launched the INSUPen® EZ in India.

Read more

Regional Offices

Haselmeier AG

Dufourstrasse 32

8008 Zürich

Switzerland

+41 44 250 52 40 +41 44 250 52 49 www.haselmeier.com
Haselmeier GmbH

Vaihinger Strasse 48

70567 Stuttgart

Germany

+49 711 719 78 0 +49 711 717 87 1
Haselmeier Inc

126 John Street

Lowell, MA 01852

United States of America

+1 978 252 3700 +1 978 710 3207
Haselmeier India Private Limited

J.R Tech Park, Building No.1, Sy No. 27/4 A2

Yarandahalli, Bommasandra Indl Area 4th Phase

Jigani Hobli, Anekal Taluk

Bangalore – 560 105

India

Contact company

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.